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Abstract- An increasing number of procedures using propofol
and remifentanil are performed by clinicians with no formal in
anesthesiology. The rapid kinetics of these drugs can rapidly
lead to adverse effects the clinician is not trained to manage.
We therefore propose to investigate through simulations drug
ratios and dosing regimens that allow esophageal
instrumentation while minimizing the probability of adverse
events. Our simulation criteria were to reach and minimize the
time above the esophageal instrumentation C95 isobol, as well as
minimize the time above the loss or responsiveness C99 and
respiratory compromise C95 isobols. A cost functional would be
developed to score each simulation. This score could be used to
identify preferred solutions. Simulations were first sorted
manually and then different cost functionals were developed to
achieve similar results. A relatively simple equation selected
80% of the runs identified manually. Further work is needed in
developing the cost functional to increase this percentage and to
add meaning to the score.

I. INTRODUCTION
Propofol in combination with opioids are commonly
administered by clinicians with no formal training in
anesthesiology for stimulating procedures of brief duration
where moderate sedation is desired. Propofol interacts
synergistically with opioids and can lead to worrisome
adverse effects including cardiovascular depression,
respiratory depression, and airway obstruction.
Many
clinicians who use these drugs do not have the skills to
properly manage these adverse events. It would therefore be
ideal to provide these clinicians with drug ratios and dosing
strategies for these procedures that would minimize adverse
effects in the majority of patients.
Recent advances in characterizing drug interactions and
high resolution modeling to predict drug behavior have
provided the theoretical means to optimize dosing to achieve
desired effects quickly, maintain those effects while avoiding
unwanted side effects, and minimize the time required for
the effects to end once delivery is terminated.
Simulations allow a wide range of dosing strategies to be
investigated for viability before conducting an actual study.
The ease of simulating, however, presents a new problem.
Thousands of simulations can be run rapidly, but a method is
needed to quickly identify viable solutions.
We propose to develop a cost functional that will return
meaningful scores for simulations of a specific procedure –
esophageal instrumentation (EI). We hypothesize that this
score can be used to 1) Identify the optimal dosing regimen
of propofol and remifentanil (bolus versus infusion versus

bolus followed by infusion, 2) Minimize the time of loss of
responsiveness and respiratory compromise while allowing
EI.
II. BACKGROUND
An increasing trend in patient care is to perform
procedures associated with mild to moderate pain outside the
operating room. Potent fast-acting anesthetics are commonly
used to blunt the response to noxious stimuli associated with
these procedures, but are often administered by clinicians
with no formal training in anesthesiology.
This study explored the behavior of two commonly used
intravenous anesthetics, propofol and remifentanil, when
used in combination to blunt the response to esophageal
instrumentation. Both drugs have unique and desired
properties. Propofol is an anesthetic, providing loss of
consciousness, preventing awareness and reducing
movement response to surgical stimuli. However, at higher
doses it frequently causes airway obstruction and loss of
consciousness. Remifentanil at higher doses can cause
respiratory depression leading to apnea.
An advantage to using these drugs in combination is their
synergistic relationship. The effects of each drug are
enhanced when they are administered together. Less of each
drug is required to achieve a desired level of sedation than if
one drug is used in isolation.
Recent developments in clinical pharmacology research
have led to the development of response surface models.
These models provide a three dimensional visualization of
combined drug behavior. Response surfaces are particularly
useful in visualizing the predicted response for all drug
combinations shown. Response surfaces for EI, loss of
consciousness (LOR) and respiratory compromise (RC)
(combination of respiratory depression and airway
obstruction) can be combined to identify ideal concentration
pairs and dosing regimens that meet clinician needs yet
provide patient safety.
Preliminary research must be conducted to collect the
data required to build these response surfaces. Advances in
technology allow further investigation to be done with
modeling. Studies have developed pharmacokinetic and
pharmacodynamic models for propofol1 and remifentanil.2
With these models, it is possible to perform simulation
studies of predicted patient response to a given stimulus over
a wide range of drug ratios and dosing strategies. The cost
functional will aid in the identification of those combinations
that closest match the defined criteria.
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Figure 1. Response surfaces for EI (A), LOR (B) and RC (C). The
remifentanil-propofol drug combinations resulting in 5% (dotted line),
50% (solid line) and 95% (dashed line) probabilities are shown.
(A) EI was considered tolerated if it was placed mid-esophageal
(~40 cm) without subject discomfort, as indicated by the subject raising
their hand, gag reflex, coughing, or greater than 20% increase in
baseline heart rate or blood pressure.
(B) LOR was defined as OAA/S < 2, which coincides with a loss of
response to shake and shout.
(C) RC is generated from the combined data of airway obstruction and
respiratory depression.

Data used to construct the response surfaces were
collected following the procedure outlined in the methods
section of last year’s paper.3 For this study, surfaces for EI,
LOR and RC were constructed (Fig. 1). Response surfaces
were generated using the Greco construct (Eq. 1).4 The line
on the surface formed when a plane drawn perpendicular to
the effect axis intersects with the surface highlights all
possible drug combinations that are expected to produce the
same effect for a specific stimulus. This line is called an
isobol, or iso-effect line, and is identified by the stimulus and
probability associated with the effect (i.e. LOR C50 is the
LOR 50% isobol, or drug combinations that produce a 50%
probability of LOR). Isobols represent the “targets” define
the different criteria.
The criteria were defined in terms of isobols. The LOR C99
isobol was defined as LOR. We wanted to minimize the
amount of time effect site (brain) concentrations were above
this line. The RC C95 isobol defined RC. We again wanted to
minimize the amount of time above this line. EI C95 isobol
defined the target that must be reached for placement of the
instrument in the esophagus. We wanted to reach this isobol
quickly while minimizing the amount of time above it.
During the study, drugs were administered using
Stanpump (http://anesthesia.stanford.edu/pkpd). Simulations
can be performed in Stanpump, but it is a time consuming
process. Therefore, a MatLab (MathWorks, Natick, MA)
implementation of Stanpump was built, thereby allowing us
to run thousands of simulations and immediately process the
results.
To minimize the iteration matrix and avoid impractical
solutions, we defined drug ranges and step sizes to match
what is clinically relevant and feasible. The simulations
assumed propofol and remifentanil would be combined and
administered together. It was also assumed that propofol
would always be 10 mg/mL. We investigated remifentanil
concentrations from 0 to 25 µg/mL, incrementing by 1.25
µg/mL each time. Because the drugs are combined, we
assumed the infusion rate would be set by propofol. Rates
from 10 to 150 µg/kg/min were investigated, with a step size
of 10 µg/kg/min. We also investigated pretreatment with
bolus injections ranging from 0 to 20 mL, incrementing by 1
mL. The patient was assumed to be 55 years old, 75 kg and
175 cm. All simulations were for a 60 minute procedure and
were run for both a male and female subject.
It was decided that the best approach would be to develop
three independent cost functionals, each of which would
evaluate just one criteria. These three independent
functionals would then be weighted and combined to yield
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the final score. By convention, the closer a score is to zero,
the closer it is to meeting all the criteria. The cost functional
inputs are:
1. Time above RC C95
2. Time above LOR C99
3. Time to EI C95
IV. RESULTS
Previous work has shown that it is not possible to both
instrument a patient’s airway and remain in the moderate
sedation range.5 It is necessary to venture into deeper
sedation for patients to tolerate instrumentation. Along with
this deeper sedation come adverse effects such as LOR and
RC. During data collection we observed that the most
stimulating part of the procedure is the actual placing of the
instrument. A patient can tolerate a placed instrument at
lower drug levels. Therefore, more drug must be given up
front, but it can then be reduced for the duration of the
procedure. Because it is impossible to perform the procedure
and avoid these adverse effects, we must instead devise a
dosing regimen that minimizes the time a patient is at drug
levels with high probabilities of them occurring.
Of the 13,230 simulations, 2,887 (12%) never reach the EI
C95 isobol. The average time above this isobol for the
remaining runs is 29.8 minutes ± 26.6. As shown in Fig 2,
the EI C95 isobol requires higher drug levels compared to
LOR and RC. There is potential for serious complications if
a patient remains at these drug levels for almost half of the
procedure. It only takes a minute or two to instrument the
airway. If we therefore only include those runs that are above
EI C95 for at least 1 minute but not more than 2.5 minutes,
we are left with 412 (3%). Their average time above the
isobol is 1.75 minutes ± 0.4.
The average time above LOR C99 of those same 412 runs
is 6.7 minutes ± 11. We will need to be above this isobol for
at least the amount of time allowed for EI. If we further
consider just those runs that are above LOR C99 for less than
6 minutes, we are left with 327 (2.5%). The average time
above the isobol drops to 3.4 minutes ± 1.2.
Finally, the mean time above the RC C95 isobol for these
327 runs is 7.1 minutes ± 11.7. After limiting these to those
runs that are above RC C95 for less than 7 minutes, 305 runs
remain (2.3%). The average time above the isobol is 4.2
minutes ± 0.6. This approach has therefore eliminated 97.7%
of the simulations. These are shown in Table 1.
Table 1. Table showing manual filtering criteria for the simulations.
The first three columns indicate the filter criteria, if any, for each time.
The fourth column indicates the number of runs that met the criteria.
The last column shows the percentage of runs that met all criteria.
EI C95
LOR
RC C95
# of
Percent
C99
Runs
>0
10,343
78
Man #1
1≤tme<2.5
412
3
Man #2
1≤tme<2.5
<6
327
2.5
Man #3
1≤tme<2.5
<6
<7
305
2.3
Man #4

Figure 2. The target isobols are shown with the results of one
simulation. A 55 year old male, 75 kg and 175 cm was pretreated with a
6 mL bolus of 10 mg/mL propofol combined with 10 µg/mL
remifentanil. This was immediately followed with a 60 minute infusion
at 40 µg/kg/min. Markers are displayed at whole minutes.

After having manually filtered the simulations, we next
attempted to develop a cost functional that would yield a
similar selection. The simplest cost functional just adds the
three times to create a score. A similar number of final
simulations can be obtained by eliminating all runs with
scores greater than 3.5 or equal to 0. This leaves 293
simulations. However, they are all unique to those obtained
previously. When manually selecting runs, all those that did
not reach EI C95 were eliminated. When the cost functional
was changed to subtract 1 from EC C95 time and to not
assign a score to any run that did not reach EI C95, 311
simulations were selected when a cutoff score of 9.5 was
used. This time, only 87 runs were unique (28%). A third
version eliminated all projects that were not above EI C95 for
at least one minute, similar to the criteria used when
manually selecting runs. Selecting just those runs with a
score less than 9.8 resulted in 301 simulations being selected,
of which 62 were unique (21%).
After looking at the isobol shapes in Fig. 2, it was noted
that RC C95 and EI C95 appeared to be concentric. This
Table 2. Table showing cost functional algorithm development for
filtering the simulations. The first three columns indicate the inclusion
criteria, if any, and well as any modification done for each time. The
fourth column indicates the score selection criteria. The fifth column
shows the number of runs that met the criteria. The last column is the
percentage of the number of runs indicated that were not included in
the manually selected approach.
EI C95
LOR
RC
Score
# of
Percent
C99
C95
Runs
Unique
>0
<3.5
293
100
CF #1
>0, tme-1
<9.5
311
28
CF #2
>1, tme-1
<9.8
301
21
CF #3
>1, tme-1
X
<5.1
314
27
CF #4
>1,
tmeX
<4.5
304
20
CF #5
2•(tme-1)
2
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means the times should be highly correlated. Therefore, it is
not necessary to include a time for both. After eliminating
time above RC C95, 314 simulations were selected by using a
cutoff score of 5.1, with 86 being unique (27%). It was noted
that previously we had also used a cutoff time for EI C95 of 2
minutes. When adding times, time above LOR C99 is almost
always greater than EI C95 time because its isobol is lower on
the plot. To give equal weight to both times, I doubled the
weight of EI C95 (multiplied by 2) and subtracted 2 from the
LOR C99 time. When using a cutoff score of 4.5, 304 runs
were selected, 60 of which were unique (20%). These are all
summarized in Table 2.

procedure requires the patient be alert, it may only be
necessary to track RC. LOR does not provide any additional
information about adverse effects. However, it does help
predict wake up times after the infusion is turned off.
Future versions of the cost functional should also consider
if spontaneous breathing stops and for how long.
Additionally, criteria for selecting the drug levels the balance
of the procedure will take place at need to be developed.
Finally, the focus of this study was to create a cost functional
that selected the same runs identified through a manual
process. Future work, including clinical trials, is necessary to
select and validate a final drug dose and dosing regimen.

V. DISCUSSION

VI. CONCLUSION

Both manual and automated dosing evaluations were able
to yield similar simulation selections. The elimination of
97.7% of simulations based upon evaluation criteria makes
the task of selecting a drug ratio and dosing regimen more
manageable. However, the filtering is a product of the
method used. The approach taken in this study used time
above three isobols. The selection might therefore identify
the fastest procedure or the longest, etc. There are other
parameters worthy of consideration when selecting a drug
ratio and dosing regimen. For example, how long it takes for
a patient to be reach the EI C95 isobol is important, as is how
long it takes them to wake up once the infusions are turned
off. Additionally, we tossed all runs that didn’t reach the EI
C95 isobol. A better approach may be to use a combination of
maximum probability obtained, the time to reach it and time
above it as well as time to return of consciousness.
It may also be worth including information about the
drugs. Respiratory depression, the more dangerous
component of respiratory compromise, is associated more
with high remifentanil effect site concentrations. Onset of
Airway obstruction, the more manageable component,
occurs at high propofol effect site concentrations. Therefore,
it is expected that a preferred dose would have a low
remifentanil/high propofol drug ratio. While this information
is incorporated already in the cost functional through
respiratory compromise, it may be helpful to include it more
directly.
Because we are running simulations, we also have the
benefit of knowing the equation that describes the lines. It
may be possible to take advantage of the Greco equation (Eq.
1), in whole or in part, to create a more dosing-dependent
score. The isobol curves are calculated using this equation. It
may also be possible to relate them somehow to develop an
equation where the meaning of the score does not change if
the isobol probability is changed.
Isobols can be drawn for any probability. In hindsight I
would propose lowering the RC isobol to C50. We do not
want RC to occur so using a lower probability would
increase the amount of time above it, increasing the score for
being above it. Also, EI and RC isobols do not match at
different probabilities. The cost functional should therefore
include it. LOR, however, may be unnecessary. Unless the

A cost functional can be developed that will reasonably
match manual filtering of simulation results. Eighty percent
of the runs identified were identical to both methods. The
cost functional could be used to eliminate 98% of the
simulations, greatly reducing the task of evaluating the
simulation results.
Manually filtering the simulation results provides a
baseline to compare the cost functional to. However, the
techniques used are easily implemented in a program,
thereby eliminating some post processing requirements.
Also, we relied just on times for the manual filtering. A cost
functional provides an opportunity to use more complex
methods. Additional information should be included in the
equation to selection of an optimal drug ratio and dosing
scheme does not rely solely on times. Finally, the current
score is not meaningful. Future work would modify the
equation so the output would provide information about that
run. So while this study looked at mimicking the results
obtained by manually filtering, future work would improve
upon it.
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